These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 30524732)
21. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India. Jain D; Darrow JJ Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078 [TBL] [Abstract][Full Text] [Related]
22. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132 [TBL] [Abstract][Full Text] [Related]
23. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy. Crager SE; Guillen E; Price M Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749 [TBL] [Abstract][Full Text] [Related]
24. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India. Satyanarayana K; Srivastava S Open AIDS J; 2010 Jan; 4():41-53. PubMed ID: 20148091 [TBL] [Abstract][Full Text] [Related]
26. Regional trade and the nutrition transition: opportunities to strengthen NCD prevention policy in the Southern African Development Community. Thow AM; Sanders D; Drury E; Puoane T; Chowdhury SN; Tsolekile L; Negin J Glob Health Action; 2015; 8():28338. PubMed ID: 26205364 [TBL] [Abstract][Full Text] [Related]
27. Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? Tenni B; Lexchin J; Phin S; Gleeson D Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):295-308. PubMed ID: 38563076 [TBL] [Abstract][Full Text] [Related]
28. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards. Cohen-Kohler JC; Forman L; Lipkus N Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618 [TBL] [Abstract][Full Text] [Related]
29. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Assefa Y; Hill PS; Ulikpan A; Williams OD Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757 [TBL] [Abstract][Full Text] [Related]
30. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines? Kerry VB; Lee K Global Health; 2007 May; 3():3. PubMed ID: 17524147 [TBL] [Abstract][Full Text] [Related]
31. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure. Jung Y; Kwon S Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858 [TBL] [Abstract][Full Text] [Related]
32. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation. Narsai K; Masekela FB; Leufkens HGM; Mantel-Teeuwisse AK BMC Health Serv Res; 2024 Jan; 24(1):111. PubMed ID: 38245720 [TBL] [Abstract][Full Text] [Related]
33. TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana. Cohen JC; Gyansa-Lutterodt M; Torpey K; Esmail LC; Kurokawa G Global Health; 2005 Dec; 1():17. PubMed ID: 16336685 [TBL] [Abstract][Full Text] [Related]
34. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning. Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142 [TBL] [Abstract][Full Text] [Related]
35. Trade, TRIPS, and pharmaceuticals. Smith RD; Correa C; Oh C Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054 [TBL] [Abstract][Full Text] [Related]
36. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Son KB; Lopert R; Gleeson D; Lee TJ Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313 [TBL] [Abstract][Full Text] [Related]
37. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. Babovic S; Wasan KM J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678 [TBL] [Abstract][Full Text] [Related]
38. Patent and exclusivity status of essential medicines for non-communicable disease. Mackey TK; Liang BA PLoS One; 2012; 7(11):e51022. PubMed ID: 23226453 [TBL] [Abstract][Full Text] [Related]
39. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines. Townsend B; Gleeson D; Lopert R Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239 [TBL] [Abstract][Full Text] [Related]
40. Compulsory patent licensing and local drug manufacturing capacity in Africa. Owoeye OA Bull World Health Organ; 2014 Mar; 92(3):214-9. PubMed ID: 24700981 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]